argenex SE $ARGX Shares Sold by First Turn Management LLC

First Turn Management LLC trimmed its stake in shares of argenex SE (NASDAQ:ARGX) by 40.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,256 shares of the company’s stock after selling 15,511 shares during the period. argenex comprises about 2.2% of First Turn Management LLC’s holdings, making the stock its 23rd biggest position. First Turn Management LLC’s holdings in argenex were worth $19,557,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Oppenheimer & Co. Inc. lifted its position in shares of argenex by 2.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after acquiring an additional 12 shares during the period. Valeo Financial Advisors LLC lifted its position in shares of argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after acquiring an additional 12 shares during the period. CI Investments Inc. lifted its position in shares of argenex by 2.6% during the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock valued at $394,000 after acquiring an additional 12 shares during the period. Sound View Wealth Advisors Group LLC lifted its position in shares of argenex by 3.4% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock valued at $292,000 after acquiring an additional 13 shares during the period. Finally, Allworth Financial LP lifted its position in shares of argenex by 12.7% during the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after acquiring an additional 13 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

Shares of argenex stock opened at $893.52 on Friday. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The company has a market capitalization of $55.57 billion, a P/E ratio of 39.78, a P/E/G ratio of 1.37 and a beta of 0.47. The business has a 50 day moving average price of $812.09 and a 200 day moving average price of $812.17.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The firm had revenue of $1.31 billion during the quarter. As a group, research analysts expect that argenex SE will post 26.19 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ARGX shares. Guggenheim lifted their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Robert W. Baird lifted their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Finally, Wells Fargo & Company lifted their price target on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research report on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,019.50.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.